









Markets
/
Stocks
/
nasdaq-pfe
/

Pfizer Inc

PFE

26.215USD

+0.115+0.44%

Market hours （ET）Quotes delayed by 15 min

149.06BMarket Cap

15.15P/E TTM



Pfizer Inc

26.215

+0.115+0.44%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Pfizer Inc

Currency: USD Updated: 2026-01-29

Key Insights

Pfizer Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 61 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 28.92.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pfizer Inc's Score

Industry at a Glance

Industry Ranking

61 / 159

Overall Ranking

159 / 4540

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Pfizer Inc Highlights

StrengthsRisks

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 119.41%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 119.41%.

Fairly Valued

The company’s latest PE is 15.09, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.85B shares, decreasing 2.24% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 110.69K shares of this stock.

Analyst Rating

Based on 29 analysts

Hold

Current Rating

28.919

Target Price

+9.13%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-01-29

The current financial score of Pfizer Inc is 7.17, ranking 128 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 16.65B, representing a year-over-year decrease of 5.92%, while its net profit experienced a year-over-year decrease of 20.69%.

Score

Industry at a Glance

Previous score

7.17

Change



Financials

6.81

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.05

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.06

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.90

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Pfizer Inc's Company Valuation

Currency: USD Updated: 2026-01-29

The current valuation score of Pfizer Inc is 8.49, ranking 18 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 15.09, which is 424.73% below the recent high of 79.17 and 3500.61% above the recent low of -513.09.

Score

Industry at a Glance

Previous score

8.49

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 61/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-01-29

The current earnings forecast score of Pfizer Inc is 6.97, ranking 123 out of 159 in the Pharmaceuticals industry. The average price target is 29.00, with a high of 37.54 and a low of 24.00.

Score

Industry at a Glance

Previous score

6.97

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 29 analysts

Hold

Current Rating

28.919

Target Price

+9.13%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Pfizer Inc

PFE

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-01-29

The current price momentum score of Pfizer Inc is 7.03, ranking 78 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 27.01 and the support level at 25.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.83

Change

0.2

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.120

Buy

RSI(14)

56.353

Neutral

STOCH(KDJ)(9,3,3)

58.624

Neutral

ATR(14)

0.543

High Vlolatility

CCI(14)

93.145

Neutral

Williams %R

39.345

Buy

TRIX(12,20)

0.117

Sell

StochRSI(14)

31.859

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

25.998

Buy

MA10

25.904

Buy

MA20

25.588

Buy

MA50

25.454

Buy

MA100

25.124

Buy

MA200

24.597

Buy

Institutional Confidence

Currency: USD Updated: 2026-01-29

The current institutional shareholding score of Pfizer Inc is 5.00, ranking 74 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 67.65%, representing a quarter-over-quarter increase of 1.21%. The largest institutional shareholder is The Vanguard, holding a total of 531.51M shares, representing 9.35% of shares outstanding, with 2.09% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

531.51M

+0.16%

State Street Investment Management (US)

299.09M

+0.94%

BlackRock Institutional Trust Company, N.A.

294.15M

+1.82%

Geode Capital Management, L.L.C.

129.01M

+1.20%

Norges Bank Investment Management (NBIM)

93.65M

+6.68%

Wellington Management Company, LLP

60.46M

-21.48%

State Farm Insurance Companies

57.66M

+0.12%

MFS Investment Management

54.96M

-24.46%

BlackRock Asset Management Ireland Limited

52.35M

-4.21%

BlackRock Investment Management (UK) Ltd.

50.76M

+3.85%

Risk Assessment

Currency: USD Updated: 2026-01-29

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Pfizer Inc is 8.92, ranking 20 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.43. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Pfizer Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.